Disease · MONDO_0005313

necrotizing enterocolitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. necrotizing enterocolitis. Diseases, record MONDO_0005313. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005313

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: necrotizing enterocolitis; Open Targets
Open Targets ID: MONDO_0005313; Open Targets
Other names: Enterocolitis, Necrotizing, NEC; Open Targets
MeSH: D020345; MeSH
NCI Thesaurus: C84915; NCI Thesaurus
Orphanet: ORPHA:391673; Orphanet
Highest stage of its drugs: Phase 3, for 12 of its 23 drugs, from ClinicalTrials.gov; Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HYDROCORTISONE	CHEMBL389621	Small molecule	Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
PENTOXIFYLLINE	CHEMBL628	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
AMOXICILLIN	CHEMBL1082	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
CLARITHROMYCIN	CHEMBL1741	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS1	Cyclooxygenase	3	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	3	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5743	Drugs and targets
ADORA2A	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 3	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 3	https://conductscience.org/library/genes/136	Drugs and targets
FAAH	Fatty-acid amide hydrolase 1	1	Anandamide amidohydrolase inhibitor	Phase 2	https://conductscience.org/library/genes/2166	Drugs and targets
PDE10A	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 3	https://conductscience.org/library/genes/10846	Drugs and targets
PDE1A	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 3	https://conductscience.org/library/genes/5136	Drugs and targets
PDE1B	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 3	https://conductscience.org/library/genes/5153	Drugs and targets
PDE1C	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 3	https://conductscience.org/library/genes/5137	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01827358	Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants	Phase 2	155	2017-07-07	Staphylococcal Infection	MUPIROCIN	Its record names the disease	ClinicalTrials.gov
NCT01222585	Metronidazole Pharmacokinetics (PK) in Premature Infants	Phase 1	24	2013-12-18	Serious Systemic Infections, Necrotizing Enterocolitis	METRONIDAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01156480	Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants	Not applicable	2	2014-03-24	Necrotizing Enterocolitis	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT04347720	Canadian National PDA Treatment Study		1,663		Patent Ductus Arteriosus, Extreme Prematurity	ACETAMINOPHEN, IBUPROFEN, INDOMETHACIN	Its record names the disease	ClinicalTrials.gov
NCT02884219	Early Treatment Versus Expectative Management of PDA in Preterm Infants	Not applicable	273		Patent Ductus Arteriosus	IBUPROFEN, INDOMETHACIN	Its record names the disease	ClinicalTrials.gov
NCT03860428	Early Treatment Versus Expectant Management of PDA in Preterm Infants	Not applicable	208		Patent Ductus Arteriosus	ACETAMINOPHEN, IBUPROFEN	Its record names the disease	ClinicalTrials.gov
NCT06048614	Saline Enema Administration in Meconium Obstruction of Prematurity and Impact on the Resolution, Feeds, Microbiome, and Gut-brain Axis.	Not applicable	95		Meconium Obstruction of Prematurity	GLYCERIN, SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02819414	Paracetamol Treatment of the Borderline Significant PDA	Phase 2	80		Patent Ductus Arteriosus	ACETAMINOPHEN	Its record names the disease	ClinicalTrials.gov
NCT06422000	Effect of Pentoxifylline Versus Probiotic on Preterm Neonates With Necrotizing Enterocolitis	Phase 3	75		Necrotizing Enterocolitis	PENTOXIFYLLINE	Its record names the disease	ClinicalTrials.gov
NCT04696003	Treatment of Classic Mid-trimester PPROM by Means of Continuous Amnioinfusion	Phase 3	68		Bronchopulmonary Dysplasia, Necrotizing Enterocolitis, Intracranial Hemorrhages	AMOXICILLIN, AZITHROMYCIN, CLARITHROMYCIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Mupirocin (Treatment) vs No Mupirocin (Control): serious adverse events	3 of 80	0 of 75	155	NCT01827358	Trial comparisons
Mupirocin (Treatment) vs No Mupirocin (Control): Primary Decolonization Efficacy- Number of Participants in the Treatment and Control Groups Who Have no Detectable S. Aureus (SA) on Direct Nasal, Umbilical, and Perianal (NUP) Cultures Obtained on Day 8.	62 of 66	3 of 64	130	NCT01827358	Trial comparisons
Mupirocin (Treatment) vs No Mupirocin (Control): Persistent Decolonization Efficacy- Number of Participants in the Treatment and Control Groups Who Have no Detectable S. Aureus (SA) on Direct Nasal, Umbilical, and Perianal (NUP) Cultures on Days 8 and 22.	21 of 46	1 of 48	94	NCT01827358	Trial comparisons

Papers from its trials13

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36477458	RESULT	1	PubMed
28710882	RESULT	1	PubMed
26283668	RESULT	1	PubMed
23587979	RESULT	1	PubMed
22065264	RESULT	1	PubMed
42637114	DERIVED	1	PubMed
36143388	DERIVED	1	PubMed
34526095	DERIVED	1	PubMed
34147090	DERIVED	1	PubMed
33952559	DERIVED	1	PubMed

1 to 10 of 13

See all 13 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005313

GET https://conductscience.org/api/diseases/v1/MONDO_0005313/drugs?page=2

API reference For AI assistants